Patrick Griffin
Keine laufenden Positionen mehr
Karriereverlauf von Patrick Griffin
Ehemalige bekannte Positionen von Patrick Griffin
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| 9 METERS BIOPHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.02.2019 | 17.07.2023 |
| Corporate Officer/Principal | 26.11.2018 | 22.02.2019 | |
| SYNERGY PHARMACEUTICALS INC | Technik-/Wissenschafts-/F&E-Leiter | 23.05.2013 | 01.11.2018 |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 19.03.2012 | 01.04.2013 |
Sanofi, Inc.
 Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a company based in New York, NY. | Corporate Officer/Principal | 01.03.2009 | 01.01.2012 |
Ausbildung von Patrick Griffin
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Retail Trade | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| 9 METERS BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
Synergy Pharmaceuticals LLC
 Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
Sanofi, Inc.
Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a company based in New York, NY. | Retail Trade |
- Börse
- Insiders
- Patrick Griffin
- Erfahrung
